Zoladex: instructions for use of capsules and solution. Zoladex: instructions for use and reviews from people Pharmacological action of Zoladex

Release form: Solid dosage forms. Pills.



General characteristics. Compound:

Active substance: goserelin acetate 10.8 mg (in terms of goserelin base)
Excipients: lactic and glycolic acid copolymer (50:50) up to a total weight of 18.0 mg (Zoladex® 3.6 mg), low molecular weight lactic and glycolic acid copolymer (95:5) and high molecular weight lactic and glycolic acid copolymer (95 :5) to a total weight of 36.0 mg (the ratio between low molecular weight and high molecular weight copolymer is 3:1, by weight) (Zoladex® 10.8 mg).
DESCRIPTION
White or cream cylindrical pieces of hard polymer material, free or practically free from visible inclusions.

Pharmacological properties:

Pharmacodynamics. Zoladex® is a synthetic analogue of natural gonadotropin-releasing hormone (GnRH). With chronic use, Zoladex® inhibits the release of luteinizing hormone (LH) by the pituitary gland, which leads to a decrease in the concentration of testosterone in the blood serum in men and the concentration of estradiol in the blood serum in women. This effect is reversible after discontinuation of therapy. Initially, Zoladex®, like other GnRH agonists, may cause a temporary increase in serum testosterone concentrations in men and serum estradiol concentrations in women. On early stages During therapy with Zoladex®, some women may experience vaginal bleeding of various durations and intensity.
In men, by approximately 21 days after administration of the first capsule, testosterone concentrations decrease to castration levels and continue to remain reduced with permanent treatment, carried out every 28 days in the case of the drug Zoladex® 3.6 mg or every 3 months in the case of the drug Zoladex® 10.8 mg. This decrease in testosterone concentration during the use of Zoladex® 3.6 mg in most patients leads to tumor regression prostate gland and to symptomatic improvement.
In women, serum estradiol concentrations also decrease approximately 21 days after administration of the first capsule of Zoladex® 3.6 mg and, with regular administration of the drug every 28 days, remain reduced to a level comparable to that observed in menopausal women. This decrease leads to positive effect with hormonal-dependent forms of breast cancer, endometriosis, uterine fibroids and suppression of the development of follicles in the ovaries. It also causes thinning of the endometrium and is the cause of amenorrhea in most patients.
After administration of Zoladex® 10.8 mg, serum estradiol concentrations in women decrease within 4 weeks after administration of the first capsule and remain reduced to levels comparable to those observed in menopausal women. With the initial use of other GnRH analogues and switching to Zoladex® 10.8 mg, suppression of estradiol levels persists. Suppression of estradiol levels leads to therapeutic effect for endometriosis and uterine fibroids.
Zoladex® 3.6 mg in combination with iron supplements has been shown to cause amenorrhea and an increase in hemoglobin levels and related hematological parameters in women with uterine fibroids and concomitant anemia.
While taking GnRH agonists, women may experience menopause. Rarely, some women do not experience a return to menstruation after finishing therapy.
Administration of Zoladex® 3.6 mg every four weeks or Zoladex® 10.8 mg every 12 weeks ensures maintenance of effective concentrations. Cumulation in tissues does not occur. The drug Zoladex® binds poorly to protein, and its half-life from the blood serum is 2 - 4 hours in patients with normal function kidney The half-life increases in patients with impaired renal function. With monthly administration of Zoladex® 3.6 mg or Zoladex® 10.8 mg, this change will not have significant consequences, so there is no need to change the dose for these patients. In patients with liver failure no significant changes in pharmacokinetics are observed.

Pharmacokinetics. Administration of Zoladex® 3.6 mg every four weeks or Zoladex® 10.8 mg every 12 weeks ensures maintenance of effective concentrations. Cumulation in tissues does not occur. The drug Zoladex® binds poorly to protein, and its half-life from the blood serum is 2 - 4 hours in patients with normal renal function. The half-life increases in patients with impaired renal function. With monthly administration of Zoladex® 3.6 mg or Zoladex® 10.8 mg, this change will not have significant consequences, so there is no need to change the dose for these patients. In patients with liver failure, significant changes in pharmacokinetics are not observed.

Indications for use:

For Zoladex® 10.8 mg
. Prostate cancer
. Endometriosis
. Uterine fibroids

Important! Get to know the treatment

Directions for use and dosage:

Adult men
Zoladex® 10.8 mg
Zoladex® 10.8 mg is administered subcutaneously into the anterior abdominal wall every 3 months.
Adult women
Zoladex® 10.8 mg is administered subcutaneously into the anterior abdominal wall every 12 weeks.
Elderly patients, patients with renal or hepatic insufficiency: no dose adjustment is required.

Features of application:

Caution should be exercised when prescribing Zoladex® to males at particular risk of ureteral obstruction or compression. spinal cord. These patients should be closely monitored during the first month of therapy. If there is compression of the spinal cord or renal failure caused by ureteral obstruction occur or develop, standard treatment for these complications should be prescribed.
. In women, Zoladex® 10.8 mg is indicated only for the treatment of endometriosis and uterine fibroids. For women requiring treatment with goserelin for other indications, Zoladex® 3.6 mg is used.
. When using Zoladex® in women, before menstruation returns, non-hormonal methods contraception.
. As with the use of other GnRH analogs, rare cases of ovarian hyperstimulation syndrome (OHSS) have been reported when using Zoladex 3.6 mg in combination with gonadotropin. It is assumed that desensitization caused by the use of Zoladex® 3.6 mg may, in some cases, lead to an increase in the required dose of gonadotropin. It is necessary to carefully monitor cycle stimulation to identify patients at risk of developing OHSS, since the severity and frequency of manifestations of the syndrome may depend on the dosage regimen of gonadotropin. Introduction human chorionic gonadotropin the person must be terminated if required.
. The use of GnRH agonists in women may cause a decrease in mineral density bone tissue. After treatment, most women experience restoration of bone mineral density. In patients receiving Zoladex® 3.6 mg for the treatment of endometriosis, the addition of hormone replacement therapy (estrogen and progestogen drugs daily) reduced the loss of bone mineral density and vasomotor symptoms. Currently, there is no experience with the use of hormone replacement therapy during treatment with Zoladex® 10.8 mg.
. The resumption of menstruation after the end of treatment with Zoladex® may be delayed in some patients. In rare cases, some women may experience menopause during treatment with GnRH analogues without menstruation returning after the end of therapy.
. The use of Zoladex® may lead to an increase in cervical resistance; caution must be exercised when dilating the cervix.
. There is no data on the effectiveness and safety of therapy with Zoladex® for benign gynecological diseases lasting more than 6 months.
. Zoladex® 3.6 mg should be used during in vitro fertilization only under the supervision of a specialist with experience in this field.
. It is recommended to use Zoladex® 3.6 mg with caution during in vitro fertilization in patients with polycystic ovary syndrome, as stimulation is possible large quantity follicles.
. Preliminary data suggest that the use of a bisphosphonate in combination with GnRH agonists in men helps reduce loss of bone mineral density. Due to the possibility of developing decreased glucose tolerance while taking GnRH agonists in men, it is recommended to periodically monitor blood glucose levels.
INFLUENCE ON THE ABILITY TO DRIVE A CAR AND OTHER MECHANISMS
Zoladex® is not known to impair these activities.

Side effects:

The frequency of occurrence of undesirable effects is presented as follows:
Often (> 1/100,< 1/10); Нечасто (> 1/1000, < 1/100); Редко (> 1/10 000, < 1/1 000); Очень редко (< 1/10 000), включая отдельные сообщения.
Neoplasms
Very rare: pituitary tumor.
Unspecified frequency: degeneration of fibromatous nodes in women with uterine fibroids.
From the outside immune system
Uncommon: hypersensitivity reactions.
Rarely: anaphylactic reactions.
From the endocrine system:
Very rare: hemorrhage into the pituitary gland.
Metabolic disorders:
Common: impaired glucose tolerance. Decreased glucose tolerance was observed in men receiving GnRH agonists. A decrease in glucose tolerance was manifested by the development diabetes mellitus or worsening blood glucose control in patients with a history of diabetes mellitus.
Infrequently: hypercalcemia(among women).
From the outside nervous system and mental sphere:
Very common: decreased libido associated with the pharmacological action of the drug and, in rare cases, leading to its withdrawal.
Common: decreased mood, depression (in women), paresthesia, spinal cord compression (in men), headache(among women).
Very rare: psychotic disorder.
From the outside of cardio-vascular system:
Very common: hot flashes associated with the pharmacological action of the drug and, in rare cases, leading to its withdrawal.
Common: myocardial infarction (in men); heart failure(in men), the risk of which increases with the simultaneous administration of antiandrogen drugs. Level change blood pressure manifesting as hypotension or hypertension. These changes are usually transient and resolve either during therapy with Zoladex® or after its cessation. In rare cases, these changes required medical intervention, including discontinuation of the drug Zoladex®.
From the skin and subcutaneous tissue:
Often: increased sweating, associated with the pharmacological action of the drug and, in rare cases, leading to its withdrawal.
Common: alopecia (in women), usually mild, including in young patients with benign neoplasms; the rash was mostly mild and often resolved with continued therapy.
Unspecified frequency: alopecia (in men), which manifests itself as hair loss throughout the body due to decreased androgen levels.
From the musculoskeletal system:
Common: arthralgia (in women), bone pain (in men). At the beginning of treatment, prostate cancer patients may often experience a temporary increase in bone pain, which is treated symptomatically.
Uncommon: arthralgia (in men).
From the genitourinary system:
Very common: erectile dysfunction (in men), dryness of the vaginal mucosa and enlargement of the mammary glands (in women).
Common: gynecomastia (in men).
Uncommon: soreness mammary glands(in men), ureteral obstruction (in men)
Rare: ovarian cyst (in women), ovarian hyperstimulation syndrome (in women, with joint use with gonadotropins).
Unspecified frequency: vaginal bleeding (in women)
Others:
Very common: reaction at the injection site (in women)
Often: reaction at the injection site (in men); temporary increase in symptoms of the disease in patients with breast cancer at the beginning of therapy.
Laboratory research:
Often: decreased bone mineral density, increased body weight.

Interaction with other drugs:

Not known.

Contraindications:

Increased sensitivity to goserelin or other GnRH analogues
- Pregnancy and lactation
- Childhood
CAREFULLY
Males are at particular risk of ureteral obstruction or spinal cord compression. During in vitro fertilization in patients with polycystic ovary syndrome.

Overdose:

Experience with drug overdose in humans is limited. In case of unintentional administration of Zoladex® ahead of schedule or at a higher dose, no clinically significant adverse events were observed. There are no data regarding overdose in humans. In case of overdose, the patient should be prescribed symptomatic treatment.

Storage conditions:

Store at temperatures below 25°C. Keep out of the reach of children. Shelf life: 3 years. Do not use after the expiration date stated on the package.

Vacation conditions:

On prescription

Package:

Capsule for subcutaneous administration prolonged action 10.8 mg in a syringe applicator with defense mechanism(Safety Glide System).
One syringe applicator is placed in a laminated aluminum envelope. An envelope with a movably attached annotation flag is placed in a cardboard box with instructions for use.


According to medical classification, Zoladex (Zoladex) refers to antitumor drugs, analogues of gonadotropin-releasing hormone. The capsule for subcutaneous administration has a prolonged effect due to active components goserelin. The medicine is produced by the English company Astra Zeneca. Read its instructions.

Composition and release form

Zoladex is presented in capsules administered subcutaneously. Their composition:

How the drug works

The drug belongs to synthetic analogues of natural gonadotropin releasing hormone; with constant use, it suppresses the release of luteinizing hormone by the pituitary gland. This leads to a decrease in the level of testosterone in the blood serum of men and estradiol in women. After discontinuation of therapy, the effect is reversible. At the first stage, the use of the drug may temporarily increase the concentrations of testosterone and estradiol.

By the 21st day of treatment in men, testosterone levels decrease to castration levels and remain in this position with constant treatment (a new capsule of 3.6 mg is introduced every 28 days, or every 3 months - 10.8 mg). Also, in women, by day 21, the level of estradiol decreases to that observed during menopause. This ends with thinning of the endometrium and the occurrence of amenorrhea.

In combination with iron supplements, Zoldex causes amenorrhea and increases hemoglobin in anemia. While taking it, menopause may occur, and after the cessation of menstruation, menstruation returns. Administration of the drug every 4–12 weeks maintains normal hormone levels. The active substances of the composition do not accumulate in tissues, bind poorly to proteins, and the half-life is 2-4 hours with normal renal function and longer with reduced renal function. In liver failure, the pharmacokinetics remain almost unchanged.

Use of the drug Zoladex

The instructions highlight a number of indications for using the product. These include:

  • prostate cancer, breast cancer;
  • endometriosis;
  • uterine fibroid;
  • the need to thin the endometrium;
  • in vitro fertilization (IVF).

Directions for use and dosage

According to the instructions, the drug with a concentration of 3.6 mg is injected subcutaneously into the abdominal wall every 28 days. It can be used for a long time malignant neoplasms, no more than six months – for benign gynecological diseases. To thin the endometrium, 2 injections are given with an interval of 4 weeks; uterine ablation is performed in the first 14 days after the second dose.

To desensitize the pituitary gland, the drug is used in IVF. During therapy, the level of estradiol in the blood serum is monitored; it reaches the required concentration between 7 and 21 days. After desensitization, doctors stimulate superovulation with gonadotropin.

The drug, with a concentration of 10.8 mg, is administered subcutaneously into the anterior abdominal wall for men every 3 months, for women every 12 weeks. Repeated courses of treatment for endometriosis are not carried out due to the risk of loss of mineralization and decrease in bone density. This can be avoided by combining Zoladex with estrogens and progestogens. If the uterus big size, then a second capsule may be needed to thin the endometrium.

For anemia caused by uterine fibroids, the drug 3.6 mg is administered in combination with iron supplements for up to 3 months before surgery. special instructions use of Zoladex from the instructions:

  1. The drug is used with caution in cases of low body mass index and in obtaining funds for complete anticoagulation.
  2. The capsule is opened and used immediately; it cannot be stored unopened.
  3. The capsule is inserted in a position in which top part The patient's body is slightly elevated. Doctors must administer the drug with caution because the inferior epigastric artery and its branches are located nearby in the abdominal wall. If you are too thin, you can damage blood vessels.
  4. The protective tabs are removed from the needle and syringe; air bubbles are not removed. The doctor pinches the patient's skin, inserts the needle at an angle of 3-45 degrees into the skin, subcutaneous tissue below the navel line, holding the needle up.
  5. The syringe cannot be used for aspiration. If the needle punctures a vessel, you need to stop the bleeding, immediately remove the needle and, if necessary, insert another capsule.
  6. It is prohibited to inject into muscles or abdominal cavity. If it becomes necessary to remove the capsule surgically, the location can be determined using ultrasound scanning.
  7. Zoladex 10.8 mg in women is used only for endometriosis and uterine fibroids; in all other cases, the drug 3.63 mg is indicated.
  8. When taking the drug until menstruation returns, women should use non-hormonal contraception. After discontinuation of treatment, periods may begin with a delay. Rarely does permanent menopause occur.
  9. The combination of Zoladex with gonadotropin can rarely lead to the development of ovarian hyperstimulation syndrome.
  10. The use of the drug may result in an increase in cervical resistance, so care must be taken when dilating the cervix.
  11. The effectiveness of Zoladex therapy for benign gynecological diseases lasting more than six months has not been established.
  12. During IVF, the drug is prescribed with caution to patients with polycystic ovary syndrome due to the possible stimulation of a large number of follicles.
  13. Taking the medication does not affect concentration.
  14. The drug should be used with caution if there is a risk of developing osteoporosis, including chronic alcoholism, smoking, heredity.

Zoladex and alcohol

Doctors strictly prohibit patients receiving Zoladex therapy from drinking alcohol. This is due to the fact that ethanol can provoke an increase in side symptoms or result in unpredictable results for human health.

Drug interactions

It is useful to study the section in the instructions for use drug interactions Zoladex with other drugs. Useful tips:

  1. Androgen deprivation therapy can prolong the QT interval, so the drug is combined with caution. antiarrhythmic drugs, antipsychotics, Amiodarone, Quinidine, Moxifloxacin, Sotalol, Disopyramide, Methadone, Ibutilide, Dofetilide.
  2. At the initial stage of therapy, three days before and 3 weeks after, antiandrogens, cyproterone acetate, are prescribed, which prevents possible side effects.
  3. A combination of a drug with estrogens and progestogens in women and with bisphosphonates in men will help reduce the incidence of decreased bone tissue density.

Side effects of Zoladex

An overdose of the drug is unlikely; if signs appear, symptomatic treatment is prescribed. Side effects of Zoladex:

  • neoplasms, pituitary tumor, degeneration of fibromatous nodes of uterine fibroids;
  • hypersensitivity;
  • diabetes;
  • hypercalcemia;
  • decreased libido;
  • decreased mood, depression, paresthesia, headache, spinal cord compression;
  • psychotic disorders;
  • hot flashes, hypotension, hypertension;
  • increased sweating, alopecia, rash;
  • arthralgia, bone pain;
  • allergy, apoplexy, anaphylaxis;
  • ureteral obstruction, ovarian cyst, vaginal bleeding;
  • pain at the injection site.

Contraindications

The drug is used with caution in cases of ureteral obstruction, spinal cord compression, and polycystic ovary syndrome. Contraindications are:

  • pregnancy, lactation;
  • childhood;
  • hypersensitivity to the components of the composition.

Terms of sale and storage

The drug is sold by prescription, stored away from children at temperatures up to 25 degrees for 3 years.

Zoladex is an antitumor drug, an analogue of gonadotropin-releasing hormone.

Pharmacodynamics

A synthetic analogue of natural GnRH. With chronic use, Zoladex® inhibits the release of LH by the pituitary gland, which leads to a decrease in the concentration of testosterone in the blood serum in men and the concentration of estradiol in the blood serum in women. This effect is reversible after discontinuation of therapy. At the initial stage, Zoladex®, like other GnRH agonists, may cause a temporary increase in serum testosterone concentrations in men and serum estradiol concentrations in women. In the early stages of therapy with Zoladex®, some women may experience vaginal bleeding of varying duration and intensity.

In men, by approximately the 21st day after administration of the first capsule, the concentration of testosterone decreases to castration levels and continues to remain reduced with continuous treatment every 3 months in the case of Zoladex® 10.8 mg. This decrease in testosterone concentration during the use of Zoladex® 10.8 mg in most patients leads to regression of the prostate tumor and symptomatic improvement.

After administration of Zoladex® 10.8 mg, serum estradiol concentrations in women decrease within 4 weeks after administration of the first capsule and remain reduced to a level comparable to that observed in menopausal women. With the initial use of other GnRH analogues and switching to Zoladex® 10.8 mg, suppression of estradiol levels is maintained. Suppressing the level of estradiol leads to a therapeutic effect in endometriosis and uterine fibroids.

While taking GnRH agonists, women may experience menopause. Rarely, some women do not return to menstruation after finishing therapy.

Pharmacokinetics

Administration of the capsule every 12 weeks ensures that effective concentrations are maintained. Cumulation in tissues does not occur. The drug Zoladex® binds poorly to protein, T1/2 of it from blood serum is 2-4 hours in patients with normal renal function. T1/2 increases in patients with impaired renal function. When Zoladex® 10.8 mg is administered every 12 weeks, this change will not have significant consequences, so there is no need to change the dose for these patients. In patients with liver failure, significant changes in pharmacokinetics are not observed.

Zoladex is an antitumor drug of synthetic origin, which is a substance with properties similar to gonadotropin-releasing hormone. Treatment is carried out against hormone-dependent prostate tumors and breast cancer.

Release form, composition and packaging

The medicine is produced by the manufacturer in the form of capsules intended for injection under the skin.

The photo shows the drug Zoladex 10.8 mg

Capsules are sold together with a syringe equipped with an applicator device for administration. The capsule with the device is placed in an aluminum bag, packed in a cardboard box.

The drug has the form of light cylindrical granules containing goserelin in quantities of 10.8 m and 3.6 mg. The active ingredient is goserelin.

Manufacturer

Produces antitumor agent AstraZeneca, UK, trade name medications – Zoladex.

Indications

Long-acting capsules containing goserelin are used in the treatment of hormone-dependent malignant and benign tumors.

Capsules with goserelin 3.6 mg

The product is intended for the treatment of:

  • benign formations of the uterus - endometriosis;

Medicine other than cancer treatment benign tumors, is used for operations that require thinning of the endometrium, as well as in the in vitro fertilization (IVF) protocol.

Goserelin capsules 10.8 mg

The drug is treated when:

  • prostate cancer;
  • uterine fibroids;
  • endometriosis.

Contraindications

It is prohibited to use:

  • pregnant women, as well as women feeding children with breast milk;
  • in childhood;
  • with individual sensitivity.

Zoladex is prescribed taking into account possible benefits for women and dangers to the fetus for women undergoing IVF in the case of polycystic ovary syndrome.

In men, the drug is used with caution if there is a risk of urine obstruction in the ureters.

Mechanism of action

Treatment with Zoladex allows you to achieve:

  • decreased testosterone hormone in men;
  • decrease in the level of the hormone estradiol in a woman.

The action of the drug is based on the ability of goserelin to reversibly block the synthesis of luteinizing hormone in the pituitary gland.

Goserelin does not accumulate in tissues. The therapeutic concentration when using Zoladex 3.6 mg lasts 28 days, when using Zoladex 10.8 mg is maintained at the required value for 12 weeks.

The half-life is up to 4 hours, with renal failure the period lengthens. Liver diseases do not affect the pharmacokinetics of the drug.

Pharmacodynamics

At the initial stage of treatment, the content of estradiol temporarily increases, and bleeding from the vagina is sometimes observed.

During in vitro fertilization, the medicine is used to desensitize the pituitary gland and reduce estradiol to 150 pmol/l, which corresponds to days 7-21 of the menstrual cycle.

After the first use of the capsule, the concentration of estradiol decreases within 3 weeks to a level comparable to the level of this hormone during menopause. To maintain a low concentration of estradiol, the patient is administered a capsule at intervals of 4 weeks.

A low concentration is necessary to achieve a therapeutic effect in suppressing hormone-dependent neoplasms - breast tumors, uterine fibroids.

A side effect of treatment is suppression of follicle maturation, thinning of the endometrium, and absence of menstruation.

Estradiol concentrations after the first use of a product containing 10.8 mg goserelin decrease to menopausal levels within 4 weeks. Therapeutic effect when using the drug in women, it is achieved against endometriosis and uterine fibroids.

Pharmacodynamics in men

After a short-term increase in testosterone, which is detected in the first stage of treatment, the concentration of testosterone gradually decreases.

By the end of 3 weeks, a level corresponding to castration is reached. Reversible testosterone reduction is required for the treatment of prostate cancer.

To achieve tumor reduction and disappearance clinical symptoms the patient is given:

  • Zoladex, in which 3.6 mg of goserelin - interval - 28 days
  • Zoladex 10.8 mg – interval – 3 months

Instructions for use

Zoladex is injected subcutaneously into the abdominal wall using a syringe applicator.

Zoladex 3.6 mg

The interval for administering the drug 3.6 mg is 28 days. The differences in tumor treatment regimens lie in the duration of the courses.

  1. Treatment of malignant tumors is a long course.
  2. Therapy for gynecological benign diseases lasts up to 6 months.
  3. Thinning of the endometrium is achieved with two injections every 28 days, ablation is carried out after 14 days.

Zoladex 10.8 mg

  • For men - the capsule is administered once at an interval of 3 months
  • Women are given injections of the drug after 12 weeks

Side effects

Rare side effects of Zoladex include:

  • Development of tumor neoplasms;
  • Pathologies of the endocrine system – hemorrhage into the pituitary gland;
  • diseases of the immune system - hypersensitivity, .

Side effects of the drug appear more often:

  • metabolic disorders - increased risk of developing diabetes mellitus, hypercalcemia;
  • pathologies of the nervous system - decreased libido, depression, headache, psychotic disorder, in men – compression of the spinal cord;
  • diseases of the urinary and reproductive system - in men erectile dysfunction, gynecomastia, ureteral obstruction are detected, for women - vaginal dryness, cyst, bleeding;
  • pathologies of the cardiovascular system - changes in blood pressure, hot flashes in women, heart attack, heart failure in men;
  • skin diseases - sweating, alopecia, rash;
  • pain in joints, bones;
  • decreased bone density, weight gain, skin irritation at the injection site.

Overdose

When the drug was accidentally administered in a large dosage, there was no deterioration in the patient's condition. There is no data on an overdose of Zoladex.

special instructions

  • There is no information about the effect of the drug on the ability to drive vehicles.
  • During treatment, women should use non-hormonal contraception.
  • Normalization of menstruation after using Zoladex may occur with a delay. There are known cases of menopause.
  • It is necessary to constantly monitor blood glucose in men during treatment with the drug due to the risk of developing diabetes.

Compatibility

Treatment with Zoladex in combination with taking iron-containing drugs leads to the cessation of menstruation.

Concomitant use with antiandrogen drugs increases the risk of heart failure in men. Zoladex should not be used with alcohol due to the risk of decreased bone mineral density.

Zoladex contains as active substance goserelin acetate , as well as the following additional components: glycol copolymer And lactic acid , and low molecular weight And high molecular weight glycol copolymer And lactic acid .

Release form

Zoladex is available in 3.6 mg and 10.8 mg capsules for subcutaneous administration.

pharmachologic effect

Antitumor drug.

Pharmacodynamics and pharmacokinetics

The drug is a synthetic analogue of natural . He inhibits allocation luteinizing hormone , due to this, the level in men and concentration in women decreases. This leads to regression of the prostate and mammary glands. In addition, the medicine is effective in preventing the development follicles in the ovaries and fibroids uterus . Leads to thinning.

Effective concentrations of Zoladex are maintained when administered subcutaneously every month. The drug is characterized by a low degree of binding to plasma proteins. The half-life is usually about 3 hours.

Indications for use

This remedy is prescribed for:

  • hormone-dependent prostate or breast cancer;
  • uterine fibroids ;
  • need for thinning endometrium before surgery;
  • endometriosis ;
  • ECO (if necessary desensitization pituitary gland).

Contraindications

The drug is contraindicated in:

  • hypersensitivity to its components and other analogues gonadotropin releasing hormone ;
  • childhood;

Side effects

Side effects when taking Zoladex are as follows:

  • SSS: arterial hypotension or hypertension ;
  • musculoskeletal system: arthralgia ;
  • skin: ;
  • nervous system: nonspecific and in rare cases apoplexy pituitary gland;
  • allergy: anaphylaxis (in rare cases).

In women, the following reactions were also identified: dryness of the vaginal mucosa, increased, mood changes, changes in libido, changes in the size of the mammary glands,. At the beginning of the course, patients with breast cancer may experience hypercalcemia , as well as temporary expression of signs and symptoms of the disease. In women with fibroids of the uterus in some cases there was suppression of development fibromatous nodes .

In men, the following side effects were also observed: reduction, swelling and painful sensations mammary glands, . In rare cases, compression of the spinal cord and obstruction of the ureteral patency have been observed. In patients with prostate cancer at the beginning of the course, a temporary increase in pain in the bones.

Instructions for use of Zoladex (Method and dosage)

Capsules are injected subcutaneously into the abdominal wall. The instructions for Zoladex 3.6 mg indicate that the medicine should be used every 4 weeks. At malignant tumors and benign gynecological pathologies The course is designed for 6 capsules.

For thinning endometrium Before the operation, injections of two capsules are administered, the interval between which is 28 days. Ablation uterus between the fourth and sixth weeks after using the first capsule.

The instructions for use of Zoladex 10.8 mg indicate that the drug must be administered every 90 days.

Overdose

No clinically significant adverse events were observed at increased doses of the drug. In case of overdose, treatment is symptomatic.

Interaction

Clinically significant effect when combined with others medicines not described.

Terms of sale

Zoladex is sold by prescription only.

Storage conditions

The drug should be stored in its original packaging at temperatures up to 25°C.

Best before date

Best before date this tool is 3 years. Using it after this time is strictly prohibited.

Analogues

Level 4 ATX code matches:

Analogs of Zoladex in pharmacies are as follows:

  • Decapeptyl Depot ;
  • Leuprorelin Sandoz;
  • Lupride Depot ;

Among them, the last drug is especially common.

Which is better - Eligard or Zoladex?

Many patients are interested in which of the two drugs is more effective: Eligard or Zoladex. Experts definitely recommend using the latter. Zoladex has fewer side effects and does not affect driving. So this drug in many cases preferable to its counterparts.

With alcohol

Application of analogues gonadotropin releasing hormone may cause decreased bone mineral density in some men. A special risk group consists of patients who often drink alcohol or undergo long-term treatment corticosteroids or anticonvulsant medications, smoke, and also have medical history . Therefore, extreme caution must be taken when using Zoladex. Men who frequently drink alcohol should consult a doctor before using the drug.

Reviews of Zoladex

Patients who leave reviews about Zoladex often report adverse reactions. They write about what appears headache , frequent menstruation , . However, the drug helps. Reviews of Zoladex indicate that for those who have done without side effects, taking this remedy turned out to be really painless and effective.

Zoladex price, where to buy

You can buy Zoladex 3.6 mg in Moscow and other Russian cities for an average of 8,400 rubles. The cost of a 10.8 mg package is about 22,000 rubles. The price of Zoladex in Ukraine is approximately 2000 hryvnia for a package of 3.6 mg and 6000 hryvnia for a package of 10.8 mg.

  • Online pharmacies in Russia Russia
  • Online pharmacies in Ukraine Ukraine

LuxPharma * special offer

    Zoladex syringe applicator 10.8 mg 1 piece

Loading...Loading...